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toxicity outcomes after combining high-dose-rate (HDR) brachytherapy with external beam radio-
therapy (EBRT) for patients with clinically localized prostate cancer.
METHODS AND MATERIALS: Between 1998 and 2009, 229 patients were treated with HDR
brachytherapy followed 3 weeks later by supplemental EBRT. The HDR brachytherapy boost con-
sisted of three fractions of 192Ir (5.5e7.5 Gy per fraction), and EBRT consisted of intensity-
modulated radiotherapy delivering an additional 45.0e50.4 Gy directed to the prostate gland and
seminal vesicles. Median follow-up was 61 months.
RESULTS: Seven-year PSA relapse-free survival for low-, intermediate-, and high-risk patients
were 95%, 90%, and 57%, respectively ( p!0.001). Among high-risk patients treated with biolog-
ical equivalent doses in excess of 190 Gy, 7-year PSA relapse-free survival was 81%. In multivar-
iate analysis, Gleason scores of $8 predicted for increased risk of biochemical failure, whereas the
use of short-term neoadjuvant androgen deprivation therapy did not influence tumor-control
outcomes even among intermediate- or high-risk patients. Seven-year incidence of distant metas-
tases for low-, intermediate-, and high-risk patients were 5%, 3%, and 17%, respectively. Seven-
year incidence of late Grade 2 and 3 genitourinary toxicities were 22.1% and 4.9%, respectively
and the 7-year incidence of Grade 2 and 3 gastrointestinal toxicities were 1% and 0.4%,
respectively.
CONCLUSION: HDR prostate brachytherapy in conjunction with supplemental EBRT results in
excellent biochemical relapse-free survival rates with a low incidence of severe late genitourinary
or gastrointestinal toxicities. The use of short-term neoadjuvant androgen deprivation did not influ-
ence long-term biochemical tumor control in this cohort.  2013 Published by Elsevier Inc. on
behalf of American Brachytherapy Society. Open access under CC BY-NC-ND license.Keywords: High-dose rate; Brachytherapy; Prostate cancer; Radiation therapy; IMRT; ToxicityIntroduction
In the radiotherapeutic management of clinically local-
ized prostate cancer, dose escalation studies have been
consistently associated with improved biochemical control
outcomes and a reduction in distant metastases [DMs
(1e5)]. Furthermore, this favorable treatment response tomber 2011; received in revised form 3 May 2012;
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blished by Elsevier Inc. on behalf of American Brachythe
.1016/j.brachy.2012.05.003higher radiation doses is most evident in patients with inter-
mediate- and high-risk disease. Therefore, in an effort to
escalate the intraprostatic dose without compromising peri-
prostatic dose coverage, external beam radiation therapy
(EBRT) has been used in combination with a high-dose-
rate (HDR) brachytherapy boost. Recent evidence from
our institution has demonstrated that the use of this combi-
nation treatment approach improves tumor control in those
patients with intermediate-risk disease and selected patients
with high-risk disease (6).
In the present study, we report our long-term efficacy
and toxicity outcomes using EBRT in combination with
HDR brachytherapy for patients with clinically localized
prostate cancer. Consistent with other reports (6e15), ourrapy Society. Open access under CC BY-NC-ND license.
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ciated with excellent tumor control rates for favorable- and
intermediate-risk patients and acceptably low rates of late
genitourinary (GU) and gastrointestinal (GI) treatment-
related toxicities.Methods and materials
Between 1998 and 2010, 229 patients with clinically
localized, biopsy-proven adenocarcinoma of the prostate
were treated with HDR brachytherapy followed 3 weeks
later by EBRT at Memorial Sloan-Kettering Cancer Center.
The clinical characteristics of patients in this study are
summarized in Table 1. The patients were stratified into
prognostic risk category groups based on the National
Comprehensive Cancer Network classification system
(www.nccn.com). This retrospective study was approved
by the internal Institutional Review Board.
The HDR brachytherapy technique in use at our institu-
tion has been described previously (15). In brief, the catheter
placement is carried out under general anesthesia using
a transperineal approach with a template-based technique
using real-time transrectal ultrasound guidance. The clinicalTable 1
Patient characteristics
Characteristics N (%)
Age (y)
!65 104 (45.4)
$65 125 (54.6)
Gleason score
6 45 (19.7)
7 137 (59.8)
8 25 (10.9)
9 20 (8.7)
10 2 (0.9)
Pretreatment PSA (ng/mL)
!10 177 (77.3)
10e20 43 (18.8)
O20 9 (3.9)
T-stage
T1eT2a 151 (65.9)
T2beT2c 60 (26.2)
T3aeT4 18 (7.9)
Neoadjuvant ADT
No 131 (57.2)
Yes 98 (42.8)
Baseline IPSS
!8 126 (72.8)
$8 47 (27.2)
NCCN risk group
Low 27 (11.8)
Intermediate 141 (61.6)
High 61 (26.6)
PSA5 prostate-specific antigen; ADT5 androgen deprivation therapy;
IPSS5 International Prostate Symptom Score; NCCN5National Compre-
hensive Cancer Network.target volume (CTV) is defined as the prostate gland and the
base of seminal vesicles, and the planning target volume is
defined as a 3-mm margin around the CTV. Treatment plan-
ning for earlier cases in the series was performed using a soft-
ware package developed at Memorial Sloan-Kettering
Cancer Center with the following constraints relative to the
prescription dose: 100% target coverage, 100e120%
maximum urethra dose, and rectal maximum dose #100%
of prescribed dose. Treatment planning for the latter part of
the series was done using Brachyvision (Varian Medical
Systems, Inc., Palo Alto, CA) with similar dose constraints.
All patients in this series were treated with 192Ir using Gam-
maMed 12i or aGammaMed Plus remote afterloader (Var-
ian). The first 45 patients were prescribed a peripheral dose
of 550 cGy per fraction, the subsequent 40 patients received
600 cGy, the next 32 patients received 650 cGy, the next 108
patients received 700 cGy per fraction (the current dose in
use at our institution), and 4 patients received 750 cGy per
fraction. Each patient was treated with HDR brachytherapy
delivered in three fractions at least 4 h apart. Patients were
typically treated on the day of the implant and subsequent
fractions were delivered on the following day with
a minimum interfraction interval of 4 h to deliver the total
dose within a 24-h time period.
Approximately 3 weeks after the HDR procedure, EBRT
was initiated using conformal techniques described previ-
ously (15). The CTV was defined for this phase of therapy
as the prostate gland and seminal vesicles. The planning
target volume was defined as a 1-cm margin around the
CTV and a 3-mm margin at the prostate rectal interface.
The first 11 patients received 4500 cGy in 25 fractions
and 1 patient received 4860 cGy; all remaining patients
(n5 216) were prescribed 5040 cGy in 28 fractions. One
patient was only able to undergo two fractions of brachy-
therapy (1400 cGy) as prescribed and underwent a course
of EBRT to a total dose of 59.4 Gy. As of 2002, all patients
were treated with intensity-modulated radiotherapy (IMRT)
technique where a five- to seven-field treatment plan was
used. EBRTwas delivered to the prostate gland and seminal
vesicles. The lymph nodes were not incorporated into the
treatment fields.
For patients who received neoadjuvant androgen depri-
vation therapy (ADT; n5 98; 42%), treatment was usually
initiated 3 months before the three-dimensional conformal
radiotherapy/IMRT and discontinued at the completion of
radiotherapy. The ADT was given to patients with large
prostates to achieve pretreatment volume reduction or to
high-risk patients, and adjuvant ADT even for high-risk
patients was not routinely given. The median duration of
ADT used in these patients was 9 months (range, 1e33
months).
The median follow-up for the entire cohort of patients
was 61.2 months (range, 3e150 months). Follow-up exam-
inations consisted of an assessment of serum prostate-
specific antigen (PSA), patient symptom assessment, and
digital rectal examination. New or worsening acute and late
Fig. 1. PSA relapse-free survival. PSA5 prostate-specific antigen.
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Cancer Institute Common Terminology Criteria for
Adverse Events toxicity scale, version 3. Acute toxicity
was defined as symptoms experienced by patients during
the course of therapy and up to 90 days from the comple-
tion of EBRT. The International Prostate Symptom Score
(IPSS) was used to assess urinary functioning (urinary
frequency, hesitancy, urgency, intermittence, weak urinary
stream, and nocturia) both before and after the treatment.
The patient’s status was determined at the time of analysis
in October 2011. The Phoenix definition of biochemical
failure (absolute nadir plus 2 ng/mL with the corresponding
date) was used for this analysis (16). Actuarial likelihood
of complication probabilities and disease-specific survival
were calculated according to the product-limit estimate (Ka-
planeMeier) method. The threshold of statistical signifi-
cance for differences was set at 0.05.Results
Tumor control and clinical outcomes
The 7-year PSA relapse-free survival rateswere 95%(95%
confidence interval [CI], 86.5e100.0%), 90% (95% CI,Table 2
Incidence and resolution of acute and late genitourinary toxicity
Genitourinary
Grade Acute, n (%) % Resolved
Median time to
resolution (mo
0 75 (32.8) d d
1 110 (48.0) 79 (71.8) 7.3
2 35 (15.3) 19 (54) 6.6
3 9 (3.9) 6 (66.7) 2.3
4 0 (0) d d84.4e96.9%), and 57% (95% CI, 38.2e80.8%) for low-,
intermediate-, and high-risk patients, respectively (Fig. 1).
The median follow-up for each risk group was 69 months
(range, 11e137 months), 64 months (range, 3e150 months),
and 47months (range, 5e140months) for low-, intermediate-
, and high-risk patients, respectively. In 206 patientswhowere
free of biochemical relapse, 142 patients (69%) were noted to
have PSA levels lower than 0.2 ng/mL at the time of last
follow-up, and the PSA was undetectable (!0.05 ng/mL) at
last follow-up in 85 (36%) of these patients.
The 7-year DMs-free survival for low-, intermediate-, and
high-risk patients were 95%, 98%, and 83%, respectively. In
the high-risk group among the 12 patients who developed
a biochemical failure, 7 patients developed evidence of
DMs at amedian of 38months after the treatment. At the time
of last follow-up, 212 patients (93%) were alive. The
incidence of prostate-specific mortality at 7 years for low-,
intermediate-, and high-risk patients were 0%, 1.1% (95%
CI, 0e3.1%), and 5.4% (95% CI, 0e16.1%), respectively.
The dose for the HDR boost ranged from 5.5 Gy 3 to
7.5 Gy 3 and were converted to biological equivalent
doses (BEDs) as described in prior reports (17, 18), and
these BED levels ranged from 171 to 226 Gy with a median
BED of 191.5 Gy. Although overall we did not appreciate
any influence of BED on outcomes across all the patients,
among high-risk patients there was apparent improved
biochemical control and DMs-free survival outcomes
among patients with BED valuesO190 Gy. Among patients
with higher BED values (n5 56), the incidence of PSA
relapse and DMs at 7 years were 19% and 11% vs. 40%
and 40%, respectively, among patients with lower BED
values (n5 5; p5 0.03 for PSA outcomes and p5 0.02
for DM outcomes).
GU toxicity
The frequency of GU toxicity is summarized in Table 2.
Thirty-five patients (15%) reported acute Grade 2 urinary
toxicity (moderate urgency, frequency, dysuria, nocturia,
or gross hematuria). Of these patients, 72% experienced
symptom resolution at a median time of 7.3 months after
therapy. Nine patients (4%) reported an acute urinary
toxicity of Grade 3, manifesting as urinary retention, which
resolved shortly with urinary catheterization. Seventy-five
patients (33%) reported no acute urinary problems. The) Late, n (%) % Resolved
Median time to
resolution (mo)
109 (47.6) d d
83 (36.2) 40 (48.2) 12.2
30 (13.1) 10 (33.3) 10.7
7 (3.1) 3 (42.9) 19.3
0 (0) d d
Table 3
Multivariate predictors of the incidence of late Grade 2 genitourinary
toxicity
Predictors p-Value HR
Age (!65 vs. $65) 0.085 2.28
ADT (no vs. yes) 0.09 2.09
IPSS (!8 vs. $8) 0.73 1.16
HR5 hazard ratio; ADT5 androgen deprivation therapy; IPSS5 In-
ternational Prostate Symptoms Score.
Age in univariate analysis is significant, p5 0.049.
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were 22% and 4.9%, respectively. None of the patients
experienced acute or late grade 4 urinary toxicity.
Pre- and posttreatment IPSS data were analyzed to eval-
uate GU toxicity levels in these patients in more detail.
Pretreatment IPSS data was recorded for 173 patients and
posttreatment IPSS data was recorded for 212 patients.
The median pretreatment IPSS was 5 (range, 0e27) with
126 patients (73%) reporting mild symptoms (IPSS,
0e7), 42 patients (24%) with moderate symptoms (IPSS,
8e19), and 5 patients (3%) with severe urinary symptoms
(IPSS, 20e35). For those patients with IPSS recorded at
the last follow-up, the median posttreatment IPSS was
5e6 (range, 0e34) with 131 patients (62%) reporting mild
symptoms, 65 patients (31%) with moderate symptoms, and
16 patients (7.5%) with severe urinary symptoms. A multi-
variate analysis, including age, the use of ADT, acute rectal
toxicity, NCCN risk group, and baseline IPSS, did not
reveal any variables predicting for increased risk of
$Grade 2 late GU toxicity (see Table 3). Because urethral
dose constraints were maintained in a tight range of
115e120% of the prescription dose, there was not a broad
range of doses to analyze the influence of the urethral dose
on toxicity in this cohort of patients.
GI toxicity
As shown in Table 4, 69 patients (30%) experienced
acute Grade 1 GI toxicity, mostly in the form of diarrhea
and pelvic discomfort. These side effects resolved in 87%
of patients at a median of 4 months after treatment. Only
2 patients (0.9%) reported a rectal toxicity of grade 2
(moderate diarrhea in both cases), which resolved in 1
patient and improved significantly in the second patient,Table 4
Incidence and resolution of acute and late gastrointestinal toxicity
Gastrointestinal toxicity
Grade Acute, n (%) Resolved, n (%)
Median time to
resolution (mo
0 158 (69.0) d d
1 69 (30.1) 60 (87.0) 4.0
2 2 (0.9) 1 (50) 10.4
3 0 (0) d d
4 0 (0) d dshortly after treatment. No patients reported acute GI Grade
3 or 4 GI toxicity.
The 7-year incidence of Grade 2 and 3 late rectal toxic-
ities were 1% and 0.4%, respectively. One patient (0.4%)
reported Grade 3 GI toxicity (daily rectal bleeding
requiring transfusion, which resolved after cauterization).
Approximately 1 year after completing radiation therapy,
1 patient was found to have a midsigmoid stricture with
fibrosis and angulation of the sigmoid distally on regular
screening colonoscopy. The patient did not complain of
abdominal pain and had regular bowel movements. The
area of the stricture was laparoscopically resected and final
pathology was consistent with diverticulitis and abscess
formation. The location of the stricture was inside the treat-
ment field of the EBRT, but outside of the high dose region
of the brachytherapy treatment volume.
Discussion
In the management of patients with intermediate- and
high-risk prostate adenocarcinoma, dose-escalation studies
have demonstrated an improvement in tumor control,
disease-free survival, and freedom from DMs (1e5, 19).
Yet, the benefits of dose escalation must be weighed against
the risks of toxicity to the surrounding normal tissue struc-
tures. For patients with disease localized to the prostate,
HDR brachytherapy has been shown to be a favorable
method of increasing the intraprostatic dose while mini-
mizing the dose to peripheral sensitive structures. Our results
indicate that a treatment regimen combining EBRT with
a HDR brachytherapy boost is associated with a low likeli-
hood of developing Grade 3 or higher GU or GI toxicities.
An interesting finding in our report was the observation
of improved outcomes in the high-risk patient cohort when
higher BED doses were delivered with the HDR. Among
patients with BED dosesO190 Gy (a/b ratio of 2), the 7-
year PSA relapse-free survival outcome for high-risk
patients was 81% compared with 60% for patients who
received lower dose levels ( p5 0.02). In addition, dose
escalation for this high-risk cohort was also associated with
a reduction in improvement in the 7-year DMs-free survival
outcomes from 60% to 89% for those who received lower
and higher BED dose levels. These improved biochemical
control outcomes for high-risk patients using higher doses
appear to be consistent with what has been reported in) Late, n (%) Resolved, n (%)
Median time to
resolution (mo)
165 (72.1) d d
62 (27.1) 36 (58.1) 9.1
1 (0.4) 0 (0) d
1 (0.4) 1 (100) 5.8
0 (0) d d
Table 5
PSA relapse-free survival outcomes for high-risk patients treated with HDR brachytherapy and EBRT
Series author Year N
Study median
follow-up (y)
EBRT
regimen (Gy/fx)
HDR brachytherapy
dose (Gy/fx)
5-Y PSA-PFS
(ASTRO, %)
5-Y PSA-PFS
(Phoenix, %)
Eulau et al. (8) 2000 22 6.1 50.40/28 12e16/4 d 49
Galalae et al. (25) 2004 359 5.3 45.6e50/25 16e23/2e4 69 d
Deger et al. (11) 2005 295 5 40e50.4/20e28 18 or 20/2 59 d
Demanes et al. (13) 2005 47 7.25 36/20 22e24/4 74 83
Pellizzon et al. (26) 2008 67 5.3 36e54/20e30 16e24/4 d 68.5
Viani et al. (27) 2009 66 5 45e50.4/25e28 20e24/4 d 71
Agoston et al. (28) 2011 61 5.1 60/30 8 or 10/1 80.6 86.4
Prada et al. (29) 2012 252 6.1 46/23 21e23/2 d 84
Present Study 57a 5.1 50.4/28 18e21/3 81
PSA5 prostate-specific antigen; ASTRO5American Society for Therapeutic Radiation and Oncology; HDR5 high-dose rate; EBRT5 external beam
radiation therapy; PFS5 progression-free survival; BED5 biological equivalent dose.
a Cohort of patients with BEDO190 Gy.
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ported the outcomes of a cohort of 472 patients with inter-
mediate- and high-risk disease treated with HDR
brachytherapy and supplemental EBRT who were followed
for a median of 8 years. The authors noted improved
biochemical control and DMs-free survival outcomes with
higher BED values. In that report, an a/b ratio of 1.2 was
assumed and a 10-year PSA relapse rate of 19% and
DMs incidence of 6% with BED valuesO268 was reported.
In our cohort of high-risk patients, it is also possible that
longer courses of ADT and the use of elective nodal irradi-
ation for this cohort could have further improved the tumor
control outcomes. We recognize that in these patients
a significant component of failure was DM. Patients devel-
oped metastases as confirmed by radionuclide bone scan
and/or positron emission tomography imaging at a median
of 38 months after treatment.
There are a several studies in addition to randomized
controlled trials, which have reported outcomes and
toxicity data for patients receiving HDR brachytherapy in
addition to EBRT. A randomized phase III trial has demon-
strated that HDR brachytherapy dose escalation resulted in
a statistically significant reduction in the incidence of acute
rectal toxicity and rectal discharge, which were considered
surrogate markers for proctitis. Additionally, in patients
with at least 2-year follow-up data available, there was
no increase in late toxicities in patients receiving the
HDR brachytherapy boost compared with the patients
who received EBRT alone (21). Another randomized trial
with a median follow-up of 8.2 years demonstrated that
the addition of a HDR brachytherapy boost was superior
to EBRT alone for patients with locally advanced-staged
prostate cancer. In that report, 29% of the patients in the
HDR combined modality arm developed a biochemical
failure compared with 61% in the EBRT arm
( p5 0.024). In addition, the incidence of a positive post-
treatment biopsy (2 years after treatment) in the HDR
arm was significantly lower compared with the EBRT
arm (24% vs. 51%; p5 0.015) (22). In a retrospective
comparison from our institution, we also demonstrated that
HDR brachytherapy combined with EBRT, especially forintermediate-risk patients, was associated with superior
biochemical control outcomes compared with outcomes
in a cohort of patients treated with high-dose IMRT (6).
An additional advantage of combined brachytherapy and
EBRT dose escalation regimens for intermediate- and
high-risk patients may be the opportunity, in selected cases,
to avoid ADT, which has not been shown to be associated
with improved outcomes (23, 24).
We recognize the limitations of this study owing to it
being a retrospective analysis, which reported on relatively
small number of patients. It is also difficult to make any
definitive conclusions regarding the BED dose advantage
we observed in this study given the small number of
patients comprising lower BED dose levels. Nevertheless,
excellent biochemical control rates for patients with favor-
able- and intermediate-risk patients were achieved with this
modality. An additional limitation of this study is that
patients with high-risk disease were generally treated with
short courses (#6e8 months) of ADT and it is possible that
the use of longer courses of ADT could have further
improved outcomes for this cohort.Conclusion
HDR brachytherapy in combination with EBRT
provides a high dose of irradiation to the prostate and is
associated with excellent tumor-control rates. Higher
BED doses were particularly important for improved local
tumor control and reduced incidence of DMs for high-risk
patients. We did not observe improved outcomes for
patients treated with short-course ADT in conjunction with
this combined-modality regimen, yet further studies will be
required to determine if longer courses of adjuvant ADT
would further improve outcomes in particular for high-
risk prostate cancer patients.
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